-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, Junshi Biosciences issued an announcement that the oral nucleoside anti-SARSCoV-2 drug VV116 tablets jointly developed by it and Wangshan Wangshui as a potential respiratory syncytial virus (RSV) inhibitor.
In the mouse model, VV116 has high oral bioavailability, good tissue distribution and significantly better antiviral effect than ribavirin, and can alleviate the pathological damage of lung tissue
VV116 is a novel oral nucleoside anti-SARS-CoV-2 drug that inhibits SARS-CoV-2 replication
RSV is a single-stranded, minus-strand, non-segmented RNA virus belonging to the family Paramyxoviridae, the genus Pneumovirus
At present, there is no safe and effective drug for the treatment of RSV infection in the world, and there is a huge unmet clinical need for a long time